JGC
ARQT icon

J. Goldman & Co’s Arcutis Biotherapeutics ARQT Stock Holding History

J. Goldman & Co’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-353,644
Closed -$6.67M – 564
2025
Q3 		$6.67M Sell
353,644
-506,616
-59% -$7.99M 0.17% 165
2025
Q2 		$12.1M Buy
860,260
+679,739
+377% +$9.53M 0.29% 114
2025
Q1 		$2.82M Sell
180,521
-432,123
-71% -$6.09M 0.07% 263
2024
Q4 		$8.53M Sell
612,644
-879,573
-59% -$9.64M 0.22% 134
2024
Q3 		$13.9M Buy
1,492,217
+180,668
+14% +$1.78M 0.39% 79
2024
Q2 		$12.2M Sell
1,311,549
-123,769
-9% -$1.12M 0.35% 96
2024
Q1 		$14.2M Buy
1,435,318
+1,267,585
+756% +$9.46M 0.46% 71
2023
Q4 		$542K Buy
+167,733
New +$456K 0.02% 261

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

J. Goldman & Co's ARQT Position: Q4 2025 in Review

J. Goldman & Co sold out of Arcutis Biotherapeutics (ARQT) in Q4 2025, closing a stake of 353,644 shares — an estimated $6.67M sold.

J. Goldman & Co first reported a position in ARQT in Q4 2023 and held it in 8 quarters. The position peaked at $14.2M in Q1 2024. 282 funds tracked by Wall St. Rank hold ARQT as of Q4 2025.

  • J. Goldman & Co reported no remaining Arcutis Biotherapeutics position as of Q4 2025 after selling out during the quarter.
  • J. Goldman & Co sold 353,644 Arcutis Biotherapeutics shares in Q4 2025, an estimated $6.67M.
  • J. Goldman & Co first reported a position in Arcutis Biotherapeutics in Q4 2023 and held it in 8 quarters.
  • J. Goldman & Co's Arcutis Biotherapeutics position peaked at $14.2M in Q1 2024.
  • 282 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q4 2025.

Based on J. Goldman & Co's 13F filing for Q4 2025, filed 17 Feb 2026.